IMMODGEL

Local Immunomodulation around implants by innovative auxiliary hydrogel-based systems encapsulating autologous and phenotype controlled macrophages

 Coordinatore Steinbeis Innovation gGmbH 

 Organization address address: WILLI BLEICHER STRASSE 19
city: STUTTGART
postcode: 70174

contact info
Titolo: Dr.
Nome: Sabine
Cognome: Müller
Email: send email
Telefono: 497219000000

 Nazionalità Coordinatore Germany [DE]
 Totale costo 7˙465˙986 €
 EC contributo 5˙851˙316 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2017-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    Steinbeis Innovation gGmbH

 Organization address address: WILLI BLEICHER STRASSE 19
city: STUTTGART
postcode: 70174

contact info
Titolo: Dr.
Nome: Sabine
Cognome: Müller
Email: send email
Telefono: 497219000000

DE (STUTTGART) coordinator 504˙590.00
2    PROTIP SAS

 Organization address address: 8 PLACE DE L HOPITAL
city: STRASBOURG
postcode: 67000

contact info
Titolo: Dr.
Nome: Nihal Engin
Cognome: Vrana
Email: send email
Telefono: +33 388103063

FR (STRASBOURG) participant 1˙124˙430.00
3    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

 Organization address address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117

contact info
Titolo: Prof.
Nome: Julia
Cognome: Kzhyshkowska
Email: send email
Telefono: +49 6213839723

DE (HEIDELBERG) participant 977˙538.00
4    UNIVERSITE DE STRASBOURG

 Organization address address: rue Blaise Pascal 4
city: Strasbourg
postcode: 67070

contact info
Titolo: Mrs.
Nome: Sandrine
Cognome: Schott-Carrière
Email: send email
Telefono: +33 368851124

FR (Strasbourg) participant 837˙157.20
5    THE UNIVERSITY OF NOTTINGHAM

 Organization address address: University Park
city: NOTTINGHAM
postcode: NG7 2RD

contact info
Titolo: Mrs.
Nome: Jill
Cognome: Harris
Email: send email
Telefono: +44115 84 66857

UK (NOTTINGHAM) participant 672˙591.80
6    PROTOBIOS OU

 Organization address address: MAEALUSE 4
city: TALLINN
postcode: 12618

contact info
Titolo: Dr.
Nome: Kaia
Cognome: Palm
Email: send email
Telefono: +372 6202222

EE (TALLINN) participant 619˙941.60
7    The Brigham and Women's Hospital, Inc.

 Organization address address: Francis Street 75
city: Boston
postcode: 2115

contact info
Titolo: Prof.
Nome: Ali
Cognome: Khademhosseini
Email: send email
Telefono: +1 6173889271

US (Boston) participant 586˙347.50
8    CONTIPRO BIOTECH SRO

 Organization address address: DOLNI DOBROUC 401
city: DOLNI DOBROUC
postcode: 56102

contact info
Titolo: Dr.
Nome: Eva
Cognome: Cerna
Email: send email
Telefono: +420 467070303
Fax: 420466000000

CZ (DOLNI DOBROUC) participant 528˙720.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

reactions    immunomodulatory    medical    inflammatory    titanium    hydrogel    significantly    implant    adverse    phenotype       optimal    immune    induced    macrophage    healing    implants    validation    decrease    caused    device    responses    immodgel    auxiliary   

 Obiettivo del progetto (Objective)

'IMMODGEL aims to identify adverse immune reactions to dental and larynx titanium implants and to develop a novel therapeutic strategy to significantly decrease the implant and medical device failure caused by these reactions via design of an innovative immunomodulatory system. The system will be designed to be fixed to an implant via an adhesive polyelectrolyte multilayer and control the immune response by autologous, phenotype modulated macrophages encapsulated in a hydrogel. The auxiliary nature of the design allows it to be adjusted to any implant, medical device or transplant. IMMODGEL will apply complex systems immunology, epidemiology, and functional approaches to identify key adverse immune reactions caused by implants and detrimental macrophage phenotypes around titanium implants. This will be used to establish the optimal biomaterial composition and cytokine delivery system for the immunomodulatory hydrogel design to revert macrophage-induced inflammatory reactions (M1) to the optimal tolerogenic and healing reactions (M2). Long-term fixation of the desired M2 phenotype will significantly decrease the level and duration of implant-induced inflammation, and optimise healing phase. The interaction of implants and medical devices with the immune system will be modelled to develop a “Foreign Body Response on-a-chip” to predict patient’s specific responses to implant materials and modify the immunomodulatory hydrogel accordingly, as a step towards personalized implants with minimal adverse reactions. The gels will be incorporated to engineered tissues for validation. Validation of the approach will be performed in vivo in animal models. Significantly suppressed inflammatory responses and optimal tissue remodelling and healing around titanium implants is expected. The key innovation will be the development of IMMODGEL as an auxiliary system to improve the outcomes of implantation and reduce the cost of implant complication and related medical costs in Europe.'

Altri progetti dello stesso programma (FP7-HEALTH)

HARP (2010)

Evaluation and impact of screening and treatment approaches for the prevention of cervical neoplasia in HIV-positive women in Burkina Faso and South Africa: HPV in Africa Research Partnership

Read More  

THERAGLIO (2013)

Microbubble driven multimodal imaging and theranostics for gliomas

Read More  

IACOBUS (2013)

"Diagnosis and Monitoring of Inflammatory and Arthritic diseases using a COmbined approach Based on Ultrasound, optoacoustic and hyperSpectral imaging"

Read More